This trial enrolled 17,604 patients with obesity and established cardiovascular disease but without diabetes
Nausea, vomiting, constipation, and diarrhea are the most frequent side effects, typically appearing during the first 12 weeks
The injection location is commonly in the upper arm, thigh, or abdomen
Researchers found that patients using semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) experienced significantly greater annualized total hip bone loss than matched controls, particularly among patients who were taking these drugs for weight loss without type 2 diabetes as an underlying condition
Medical organizations in Canada and abroad have long recognized obesity as a chronic condition, rather than a lifestyle choice